351 related articles for article (PubMed ID: 23100499)
1. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.
Falzon D; Gandhi N; Migliori GB; Sotgiu G; Cox HS; Holtz TH; Hollm-Delgado MG; Keshavjee S; DeRiemer K; Centis R; D'Ambrosio L; Lange CG; Bauer M; Menzies D;
Eur Respir J; 2013 Jul; 42(1):156-68. PubMed ID: 23100499
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.
Diriba G; Alemu A; Yenew B; Tola HH; Gamtesa DF; Mollalign H; Eshetu K; Moga S; Abdella S; Tollera G; Kebede A; Dangisso MH
Int J Infect Dis; 2023 Jul; 132():50-63. PubMed ID: 37072053
[TBL] [Abstract][Full Text] [Related]
4. Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects.
Yew WW
Kekkaku; 2011 Jan; 86(1):9-16. PubMed ID: 21401001
[TBL] [Abstract][Full Text] [Related]
5. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
[TBL] [Abstract][Full Text] [Related]
6. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
[TBL] [Abstract][Full Text] [Related]
8. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs.
Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K
Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401
[TBL] [Abstract][Full Text] [Related]
12. Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: update 2012.
Chang KC; Yew WW
Respirology; 2013 Jan; 18(1):8-21. PubMed ID: 22943408
[TBL] [Abstract][Full Text] [Related]
13. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
[TBL] [Abstract][Full Text] [Related]
15. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB.
Hwang SS; Kim HR; Kim HJ; Kim MJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Eur Respir J; 2009 Mar; 33(3):581-5. PubMed ID: 19251799
[TBL] [Abstract][Full Text] [Related]
16. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates].
Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E
Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903
[TBL] [Abstract][Full Text] [Related]
18. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.
Chand AB; Basnet A; Maharjan B; Rai G; Joshi YP; Bhatt LR; Sen B; Rai SK
PLoS One; 2024; 19(5):e0301210. PubMed ID: 38709710
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.
Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J
Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic resistance acquisition versus primary transmission in the presentation of extensively drug-resistant tuberculosis.
O'Toole RF
Int J Mycobacteriol; 2022; 11(4):343-348. PubMed ID: 36510916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
